Molecular mimicry in the chronic myeloproliferative disorders: reciprocity between quantitative JAK2 V617F and Mpl expression
about
Mpl traffics to the cell surface through conventional and unconventional routesGenomic landscape of megakaryopoiesis and platelet function defectsGuidelines for the management of myeloproliferative neoplasmsPhenotypic variations and new mutations in JAK2 V617F-negative polycythemia vera, erythrocytosis, and idiopathic myelofibrosisThrombopoietin and hematopoietic stem cells.Human-induced pluripotent stem cells from blood cells of healthy donors and patients with acquired blood disordersDifferential sensitivity to JAK inhibitory drugs by isogenic human erythroblasts and hematopoietic progenitors generated from patient-specific induced pluripotent stem cellsSex differences in the JAK2 V617F allele burden in chronic myeloproliferative disorders.Hydroxycarbamide: a user's guide for chronic myeloproliferative disorders.JAK2 and MPL protein levels determine TPO-induced megakaryocyte proliferation vs differentiation.Two clinical phenotypes in polycythemia vera.Gender and Vascular Complications in the JAK2 V617F-Positive Myeloproliferative Neoplasms.Phenotype and genotype in the myeloproliferative disorders.Phenotypic variability within the JAK2 V617F-positive MPD: roles of progenitor cell and neutrophil allele burdens.Clinical relevance of JAK2 (V617F) mutant allele burdenCould hypoxia increase the prevalence of thrombotic complications in polycythemia vera?Anagrelide: 20 years later.Potential of human induced pluripotent stem cells derived from blood and other postnatal cell types.Experimental therapeutics for patients with myeloproliferative neoplasias.Janus kinase 2 inhibitors in myeloproliferative disorders.Activation of Janus kinase/signal transducers and activators of transcription pathway involved in megakaryocyte proliferation induced by vanadium resembles some aspects of essential thrombocythemia.Quantitative determination of JAK2 V617F by TaqMan: An absolute measure of averaged copies per cell that may be associated with the different types of myeloproliferative disordersAge-related differences in disease characteristics and clinical outcomes in polycythemia vera.JAK2V617F mutation status and allele burden in classical Ph-negative myeloproliferative neoplasms in Japan.Molecular Pathogenesis of Myeloproliferative Neoplasms: Influence of Age and Gender.Evaluation of clinical and laboratory findings with JAK2 V617F mutation as an independent variable in essential thrombocytosis.Second malignancies in hydroxyurea and interferon-treated Philadelphia-negative myeloproliferative neoplasms.JAK2-V617F mutation analysis of granulocytes and platelets from patients with chronic myeloproliferative disorders: advantage of studying platelets.Open-label study of oral CEP-701 (lestaurtinib) in patients with polycythaemia vera or essential thrombocythaemia with JAK2-V617F mutation.Evaluation of the JAK2-V617F gene mutation in Turkish patients with essential thrombocythemia and polycythemia vera.A higher JAK2 V617F-mutated clone is observed in platelets than in granulocytes from essential thrombocythemia patients, but not in patients with polycythemia vera and primary myelofibrosis
P2860
Q24299221-276E874E-F970-4822-829A-87F0A68A4E09Q26770869-F9104384-A9A5-4E12-815F-B7C5466221A0Q26778326-491BE5B6-32F1-4230-8868-44F97D02E572Q28756161-5F0B7378-1FEB-4833-8F55-F05E571C5BD8Q33394846-9F7284F1-866A-4D6A-A083-3676863DBDD1Q33560423-98C6D9EE-7CEF-4C8E-B83D-441582D1B360Q33894805-47334080-575A-44E6-AA32-6D1F59447F3FQ33952753-F685B0E6-D0CB-4993-9D33-9FD8B1ACC5FFQ34171747-C277718D-15CB-4486-BB59-C97D2C16C0FCQ34293019-03F26D21-6CF1-4B49-B947-B641DD4F913FQ34415448-8FAB5F62-5F7F-418F-A819-291AA39FA70CQ35433425-F9151C18-6E21-43FC-B9CF-6939360A7C63Q36922489-20D1ADCD-9541-46ED-A6CD-81423772C864Q37009717-863812C5-9EE8-4831-A879-0FDA403FD1C4Q37059441-7C47D531-2A08-4AD5-89BA-2390745908CEQ37229486-250436B3-9E50-4B37-B4A8-405C4DF33540Q37357291-74825570-D276-4E5A-8423-B8F7886DB41EQ37772900-A0E90B9C-5D92-4AE7-92C9-1783479882A9Q37797983-814AD664-26B1-4D68-BF10-05FB7103BAF7Q37815509-F9F60B4A-CF5C-4E8D-A040-9DB8C3558075Q42242382-F4EB0017-53A1-4DA3-BF85-A3E42F76AC13Q42793928-C5035DA0-856A-4917-852D-355D7D7047CFQ45382720-EF8198A3-17D3-4C0A-9C18-2CB11CE06A98Q45797468-67FE851A-756B-4C82-9DC3-6C68EB65C609Q49834761-9FB3C617-D413-40DC-BC28-4E0CA02DD864Q50466203-1611DC6A-445F-4755-917F-8529C59A1C7FQ51608068-AC806385-4F14-47F9-86CD-07A2A4DF15E3Q53528063-D8A4B292-0D87-43B8-8A30-7FFF8A265986Q54346714-EC26635B-584B-43DC-96BF-6D85D180E33CQ54502586-3DF5B565-1E9D-45A5-B20A-B025F6D69CBFQ58010175-39331244-BCB5-4219-B567-30E45EF6FCAD
P2860
Molecular mimicry in the chronic myeloproliferative disorders: reciprocity between quantitative JAK2 V617F and Mpl expression
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
2006年论文
@zh
2006年论文
@zh-cn
name
Molecular mimicry in the chron ...... JAK2 V617F and Mpl expression
@ast
Molecular mimicry in the chron ...... JAK2 V617F and Mpl expression
@en
type
label
Molecular mimicry in the chron ...... JAK2 V617F and Mpl expression
@ast
Molecular mimicry in the chron ...... JAK2 V617F and Mpl expression
@en
prefLabel
Molecular mimicry in the chron ...... JAK2 V617F and Mpl expression
@ast
Molecular mimicry in the chron ...... JAK2 V617F and Mpl expression
@en
P2093
P2860
P1433
P1476
Molecular mimicry in the chron ...... JAK2 V617F and Mpl expression
@en
P2093
Alison R Moliterno
Donna M Williams
Jerry L Spivak
Ophelia Rogers
P2860
P304
P356
10.1182/BLOOD-2006-03-008805
P407
P577
2006-08-15T00:00:00Z